Journal articles on the topic '004:61'
To see the other types of publications on this topic, follow the link: 004:61.
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the top 50 journal articles for your research on the topic '004:61.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.
1
Beltrame, André B., and Sérgio Florentino Pascholati. "Cianobactérias e algas reduzem os sintomas causados por Tobacco vosaic virus (tmv) em plantas de fumo." Summa Phytopathologica 37, no. 2 (June 2011): 140–45. http://dx.doi.org/10.1590/s0100-54052011000200010.
Full textAbstract:
As algas e as cianobactérias produzem uma grande diversidade de compostos com atividade biológica direta sobre microrganismos ou agem como ativadores de mecanismos de resistência em plantas. Em vista disso, foi investigada a manifestação dos sintomas causados pelo Tobacco mosaic virus (TMV) em plantas de fumo previamente tratadas com cianobactérias ou algas. Quando as folhas plantas de fumo foram tratadas dois dias antes da inoculação, foi verificado que suspensões de células dos isolados de cianobactérias 004/02, 008/02, Anabaena sp. e Nostoc sp. 61; e do isolado de alga 061/02, bem como as preparações do conteúdo intracelular do isolado 004/02 (4 C) e do filtrado do meio de cultivo do isolado 061/02 (61 M) apresentaram efeito na redução do número de lesões locais provocadas por TMV em folhas de plantas fumo, cultivar TNN. Além disso, foi observado que os isolados Anabaena sp., Nostoc sp. 21 (cianobactéria), Nostoc sp. 61 e 090/02 (alga) mostraram efeito direto sobre o vírus semi-purificado. Em vista disso, pode-se sugerir que os isolados estudados sintetizam compostos que agem diretamente sobre o TMV e/ou ativam o mecanismo de defesa de plantas contra fitopatógenos.
2
Lasdya, Devi, Putri Hana Pebriana, Muhammad Syahrul Rizal, Ersis Warmansyah Abbas, and Rusmaniah Rusmaniah. "Improving Beginning Reading Skills Using Word Card Media for Grade 1 Students at SDN 004 SALO." Innovation of Social Studies Journal 3, no. 2 (March 15, 2022): 83. http://dx.doi.org/10.20527/iis.v3i2.4192.
Full textAbstract:
Penelitian ini dilatar belakangi rendahnya keterampilan membaca permulaan siswa kelas I SDN 004 Salo. Salah satu solusi untuk mengatasi masalah ini adalah dengan menggunakan media kartu kata. Tujuan penelitian ini untuk meningkatkan keterampilan membaca siswa kelas I pada tema Diriku dengan menggunakan media kartu kata. Metode penelitian ini adalah Penelitian Tindakan Kelas (PTK) yang dilaksanakan dalam dua siklus. Setiap siklus terdiri dari dua pertemuan dan empat tahapan yakni perencanaan, pelaksanaan, observasi, refleksi, dan waktu penelitian dilaksanakan pada Juli sampai September. Subjek penelitian ini siswa kelas I yaitu berjumlah 21 orang. Teknik pengumpulan berupa dokumentasi, observasi dan tes. Hasil penelitian ini disimpulkan bahwa keterampilan membaca permulaan siswa dengan tema Diriku pada siklus I tergolong kurang dengan presentase ketuntasan siswa dengan nilai rata-rata 61% Sedangkan pada siklus II mengalami peningkatan baik yakni ketuntasan siswa 85%. Dengan demikian dapat disimpulkan bahwa dengan menggunakan media kartu kata dapat meningkatkan keterampilan membaca permulaan siswa kelas I SDN 004 Salo.
3
Muharis, Muharis. "PENERAPAN MEDIA GAMBAR UNTUK MENINGKATKAN HASIL BELAJAR PJOK SISWA KELAS IV SD NEGERI 004 TEMBILAHAN KOTA KECAMATAN TEMBILAHAN." Primary: Jurnal Pendidikan Guru Sekolah Dasar 6, no. 1 (April 28, 2017): 364. http://dx.doi.org/10.33578/jpfkip.v6i1.4114.
Full textAbstract:
This study is peneilitian class action was motivated by the low learning PJKO fourth grade students SD Negeri 004 Tembilahan Kota. This is evident from the acquisition value of the average students who are still under the KKM is equal to 56,00 being KKM specified value is 61, other than that of the 20 students only 7 (35.00%) students who completed their study results. Based on this the researchers applied media with the aim of improving student learning outcomes PJOK. This classroom action research conducted in SD Negeri 004 Tembilahan Kota in the fourth grade with the number of students 20 students, the study was conducted 2 cycles and be done with four stages: planning, implementation, observation, and reflection. The results showed that after the implementation of learning media, learning outcomes PJOK increase, evidenced by the acquisition: "At the initial data is the number of students who completed 7 students (35.00%) with an average nilaia 56.00, in the first cycle increased by the number of students who completed totaling 13 students (65.00%) with the average value of students increased to 72.50. And the second cycle learning outcomes increased with the number of students who completed the acquisition of up to 19 students (95.00%) with the acquisition value by an average of 83.25. Based on this acquisition can be concluded that the application of instructional media can improve learning outcomes PJOK fourth grade students SD Negeri 004 Tembilahan Kota.
4
Pistella, Christine L. Young, and Frank A. Bonati. "Communication about Sexual Behavior among Adolescent Women, Their Family, and Peers." Families in Society: The Journal of Contemporary Social Services 79, no. 2 (April 1998): 206–11. http://dx.doi.org/10.1606/1044-3894.1814.
Full textAbstract:
Adolescent pregnancy and sexually transmitted disease rates in the United States are among the highest among developed nations. A survey of female adolescent family planning patients (N = 249) indicated that teens 13 to 16 years of age were more likely than teens 17 to 1 9 years of age to discuss sexual behavior with adult, nonparental relatives (43% vs. 26%, p = .007). Teens with a prior pregnancy were more likely than never-pregnant teens to report parental discussion of contraception choices (83% vs. 53%, p = .004) and of sites for contraceptive care (61% vs. 37%, p = .0023). Adolescents rely on a complex network of family and peers for communication about sexuality. Social work clinical and community skills facilitate family-centered reproductive health training and counseling for improved reproductive health of U.S. adolescents.
5
Bacher, Ulrike, Torsten Haferlach, Claudia Schoch, Wolfgang Kern, and Susanne Schnittger. "Implications of NRAS mutations in AML: a study of 2502 patients." Blood 107, no. 10 (May 15, 2006): 3847–53. http://dx.doi.org/10.1182/blood-2005-08-3522.
Full textAbstract:
We analyzed 2502 patients with acute myeloid leukemia at diagnosis for NRAS mutations around the hot spots at codons 12, 13, and 61 and correlated the results to cytomorphology, cytogenetics, other molecular markers, and prognostic relevance of these mutations. Two hundred fifty-seven (10.3%) of 2502 patients had NRAS mutations (NRASmut). Most mutations (112 of 257; 43.6%) were found at codon 12, mostly resulting in changes from glycine to asparagine. The history of AML did not differ significantly in association with NRAS mutations. The subgroups with inv(16)/t(16;16) and inv(3)/t(3;3) showed a significantly higher frequency of NRASmut (50 of 133, 37.6% [P < .001], and 11 of 41, 26.8% [P = .004], respectively) than the total cohort. In addition, in these 2 subgroups, mutations of codon 61 were significantly overrepresented (both P < .001). In contrast, NRAS mutations were significantly underrepresented in t(15;17) (2 of 102; 2%; P = .005) in the subgroup with MLL/11q23 rearrangements (3 of 77; 3.9%; P = .061) and in the complex aberrant karyotype (4 of 258; 1.6%; P < .001). Overall, we did not find a significant prognostic impact of NRASmut for overall survival, event-free survival, and disease-free survival. However, there was a trend to better survival in most subgroups, especially when other molecular markers (FLT3-LM, MLL-PTD, and NPM) were taken into account.
6
Ribeiro, Rita de Cássia Helú Mendonça, Erica Santiago, Daniela Comelis Bertolin, Daniela Favaro Ribeiro, Claudia Bernardi Cesarino, and Emmanuel Almeida Burdmann. "Depressão em idosos portadores de insuficiência renal crônica em tratamento hemodialítico." Acta Paulista de Enfermagem 22, spe1 (2009): 505–8. http://dx.doi.org/10.1590/s0103-21002009000800010.
Full textAbstract:
OBJETIVOS: Caracterizar idosos com insuficiência renal crônica submetidos à hemodiálise em um hospital escola e identificar níveis de depressão na população estudada. MÉTODOS: Trata-se de uma pesquisa descritiva - exploratória, de natureza quantitativa utilizando a Geriatric Depression Scale (GDS) e questionário de caracterização populacional, sendo entrevistados 61 pacientes. Na análise dos dados foi utilizado método quantitativo progressivo (porcentagem) e correlação de Spearmann. RESULTADOS: A média de idade foi de 69,97±7,51 anos, 57% eram do sexo masculino, 79% de cor branca, 72% eram casados, sendo 26% analfabetos. A média de respostas depressivas foi 10,43±4,37, o que sugere humor normal-levemente deprimido na população em geral. CONCLUSÃO: Houve correlação estatisticamente significativa entre renda mensal familiar e escolaridade (valor p=0, 004) e escore GDS e analfabetismo (p=0,028), mostrando que os analfabetos apresentaram mais respostas depressivas, sugerindo menor capacidade de adaptabilidade/resiliência desses indivíduos à doença e suas implicações.
7
Moussa, Carolyne, Nikia Ross, Philippe Jolette, and Amanda J. MacFarlane. "Altered folate metabolism modifies cell proliferation and progesterone secretion in human placental choriocarcinoma JEG-3 cells." British Journal of Nutrition 114, no. 6 (August 24, 2015): 844–52. http://dx.doi.org/10.1017/s0007114515002688.
Full textAbstract:
AbstractFolate is an essential B vitamin required forde novopurine and thymidylate synthesis, and for the remethylation of homocysteine to form methionine. Folate deficiency has been associated with placenta-related pregnancy complications, as have SNP in genes of the folate-dependent enzymes, methionine synthase (MTR) and methylenetetrahydrofolate dehydrogenase 1 (MTHFD1). We aimed to determine the effect of altered folate metabolism on placental cell proliferation, viability and invasive capacity and on progesterone and human chorionic gonadotropin (hCG) secretion. Human placental choriocarcinoma (JEG-3) cells cultured in low folic acid (FA) (2 nm) demonstrated 13 % (P<0·001) and 26 % (P<0·001) lower proliferation, 5·5 % (P=0·025) and 7·5 % (P=0·004) lower invasion capacity, and 5 to 7·5 % (P=0·004–0·025) lower viability compared with control (20 nm) or supplemented (100 nm) cells, respectively. FA concentration had no effect on progesterone or hCG secretion. Small interfering RNA (siRNA) knockdown ofMTRgene and protein expression resulted in 17·7 % (P<0·0001) lower proliferation and 61 % (P=0·014) higher progesterone secretion, but had no effect on cell invasion and hCG secretion. siRNA knockdown ofMTHFD1gene expression in the absence of detectable changes in protein expression resulted in 10·3 % (P=0·001) lower cell proliferation, but had no effect on cell invasion and progesterone or hCG secretion. Our data indicate that impaired folate metabolism can result in lower trophoblast proliferation, and could alter viability, invasion capacity and progesterone secretion, which may explain in part the observed associations between folate and placenta-related complications.
8
Nugraha, Harry G., Syawaluddin Hilman, Leni Santiana, Dian K. Dewi, Wilson M. Raffaelo, Arief Wibowo, Raymond Pranata, and Eppy B. Aristiady. "Drug-Coated Balloon Versus Drug-Eluting Stent in Patients With Femoropopliteal Artery Disease: A Systematic Review and Meta-Analysis." Vascular and Endovascular Surgery 56, no. 4 (February 28, 2022): 385–92. http://dx.doi.org/10.1177/15385744211051491.
Full textAbstract:
Objective In this systematic review and meta-analysis, we aimed to compare drug-coated balloon (DCB) to drug-eluting stent (DES) in patients with femoropopliteal lesions in terms of restenosis, target lesion revascularization (TLR), and mortality. Methods A comprehensive literature search was performed through PubMed, Scopus, and Embase databases. The intervention group was patients receiving percutaneous balloon angioplasty using the DCB. The control group was patients receiving percutaneous intervention using the DES. The primary outcome was restenosis, and the secondary outcomes were TLR and mortality. Results There were 4 studies comprising 812 patients (906 lesions) included in this systematic review and meta-analysis. The rate of restenosis was .19 [.13, .26] in DCB and .24 [.20, .28] in DES. There was a trend toward lower rate of restenosis (OR .73 [.52, 1.03], P = .074; I2: 46.3%) for DCB use compared to DES use. The rate of TLR was .11 [.08, .14] in DCB and .17 [.14, .21] in DES. TLR was lower (OR .61 [.41, .92], P = .017; I2: 1.2%) in the DCB group compared to the DES group. There were no significant differences in mortality (OR 1.38 [.78, 2.44], P = .268; I2: 0%) among the two groups. Meta-regression analysis showed that the rate of restenosis in DCB in this pooled analysis was affected by sex (reference: male, coefficient −.004, P = .009), smoking (coefficient: .003, P = .010), and total occlusion (coefficient: .008, P = .004). Conclusion DCB use in patients with femoropopliteal lesion was associated with similar rate of restenosis, lower TLR, and similar mortality rate compared to DES use.
9
Beshgetoor, Donna, and Jeanne F. Nichols. "Dietary Intake and Supplement Use in Female Master Cyclists and Runners." International Journal of Sport Nutrition and Exercise Metabolism 13, no. 2 (June 2003): 166–72. http://dx.doi.org/10.1123/ijsnem.13.2.166.
Full textAbstract:
This study compared the dietary intakes of supplementing (SA) and non-supplementing athletes (NSA). Twenty-five female master athletes (mean age = 50.4 yr) participated in the study (SA = 16, NSA = 9). Four-day diet records were analyzed using Nutritionist V. Statistical significance (p < .005) was determined by independent t tests. No significant differences were observed in intakes of kilocalories (SA = 2079 ± 628 kcals, NSA = 2001 ± 435 kcals), protein (SA = 104 ± 75 g, NSA = 84 ± 35 g), fat (SA = 65 ± 39 g, NSA = 61 ± 22 g), or carbohydrates (SA = 269 ± 112 g, NSA = 277 ± 43 g). Mean intakes exceeded Dietary Reference Intake (DRI) guidelines for all micro-nutrients except calcium and vitamin E (NSA = 79% and 87% of DRI, respectively). SA had significantly greater total intakes than NSA for calcium (p = .0001), magnesium (p = .004), vitamin C (p = .003), and vitamin E (p = .001). Results suggest that female master athletes may rely on dietary supplements rather than nutrient-dense food choices to provide daily nutritional needs.
10
Proulx, Christine, Hanamori Skoblow, and Sae Hwang Han. "Marital Quality and Mental Health Among Caregiving Dyads." Innovation in Aging 4, Supplement_1 (December 1, 2020): 583. http://dx.doi.org/10.1093/geroni/igaa057.1943.
Full textAbstract:
Abstract We examined whether the associations between marital quality and mental health were equally strong among dyads in which one spouse was providing care to a spouse (n = 155), parent (n = 61), or another adult (n = 176). Using Wave 2 of the NSHAP and actor-partner interdependence (APIM) models, we found significant differences (p=.004) among groups. Marital quality was negatively associated with one’s own depressive symptoms (b=-1.29) for husbands in the spousal caregiver group, whereas marital quality was negatively associated with one’s own depressive symptoms for wives in both the parental (b=-1.27) and other adult (b=-1.96) caregiver groups. The only partner effect was the negative association between wives’ marital quality and husbands’ depressive symptoms (b=-2.59) among dyads in which one spouse was a parental caregiver. These results point to the importance of understanding the context of caregiving when examining the protective effect of spouses’ marital quality on mental health.
11
Karakas, Cemal, Emin Fidan, Kapil Arya, Troy Webber, and Joan B. Cracco. "Frequency, Predictors, and Outcome of Seizures in Patients With Myelomeningocele: Single-Center Retrospective Cohort Study." Journal of Child Neurology 37, no. 1 (November 24, 2021): 80–88. http://dx.doi.org/10.1177/08830738211053132.
Full textAbstract:
To determine the frequency, predictors, and outcomes of seizures in patients with myelomeningocele, we retrospectively analyzed the data from patients with myelomeningocele followed longitudinally at a single center from 1975 to 2013. We identified a total of 122 patients (61% female). The mean follow-up duration was 11.1 years (minimum-maximum = 0-34.5 years, SD = 8.8, median = 9.1 years). A total of 108 (88.5%) patients had hydrocephalus, and 98 (90.7%) of those patients required a ventriculoperitoneal shunt procedure. Twenty-four (19.7%) patients manifested with seizures, 23 of whom had hydrocephalus. The average age of seizure onset was 4.8 years (median 2 years of age). Falx dysgenesis ( P = .004), lumbar myelomeningocele ( P = .007), and cortical atrophy ( P = .028) were significantly associated with epileptic seizure development. The average seizure-free period at the last follow-up in patients with a history of myelomeningocele and seizures was 8.1 years. We conclude that myelomeningocele patients with seizures have an overall good prognosis with considerable long-term seizure freedom.
12
Aït-Mansour, K., P. Ruffieux, W. Xiao, R. Fasel, P. Gröning, and O. Gröning. "Nucleation and growth of C60overlayers on the Ag/Pt(111) dislocation network surface." Journal of Physics: Conference Series 61 (March 1, 2007): 16–21. http://dx.doi.org/10.1088/1742-6596/61/1/004.
Full text
13
Gollapudy, Suneeta, Drake A. Gashkoff, David M. Poetker, Todd A. Loehrl, and Matthias L. Riess. "Surgical Field Visualization during Functional Endoscopic Sinus Surgery: Comparison of Propofol- vs Desflurane-Based Anesthesia." Otolaryngology–Head and Neck Surgery 163, no. 4 (May 26, 2020): 835–42. http://dx.doi.org/10.1177/0194599820921863.
Full textAbstract:
Objective To assess if the type of general anesthetic affects bleeding and field visualization during endoscopic sinus surgery. Study Design Prospective, randomized, controlled trial. Setting Academic teaching hospital and Veterans Affairs hospital in the United States. Subjects and Methods Seventy patients were randomized to 1 of 3 anesthetic regimens: (1) the volatile anesthetic desflurane (n = 22), (2) intravenous anesthesia with propofol (n = 25), or (3) a combination of propofol and desflurane (n = 23). Intravenous remifentanil was titrated to decrease the mean arterial pressure to 60 to 70 mm Hg but not ≥30% from baseline. Surgical bleeding scores were recorded along with bleeding rates and hemodynamic parameters, including cardiac output and systemic vascular resistance through pulse contour analysis from a radial arterial line. Statistics: multiple comparison tests and regression analyses; α = .05. Results There were no differences in bleeding rate (median, 0.58, 0.85, 0.57 mL min–1), bleeding score (2.1, 2.0, 2.0), surgery duration (79, 81, 86 minutes), extubation time (9, 7, 8 minutes), recovery room time (65, 61, 61 minutes), or any hemodynamic parameters among groups 1 through 3, respectively. Group 1 required lower remifentanil infusions than group 2 (0.11 vs 0.26 µg kg–1 min–1; P = .01). The bleeding score correlated positively with height ( P = .014) and the Lund-MacKay score ( P = .013). Bilateral vs unilateral surgery led to longer surgery duration ( P = .001) and recovery room time ( P = .004). Conclusion When remifentanil is used for controlled hypotension, propofol has no advantage over desflurane to improve surgical field visualization during functional endoscopic sinus surgery.
14
Sarris, Andreas H., Ira Braunschweig, L. Jeffrey Medeiros, Madeleine Duvic, Chul S. Ha, M. Alma Rodriguez, Frederick B. Hagemeister, et al. "Primary Cutaneous Non-Hodgkin’s Lymphoma of Ann Arbor Stage I: Preferential Cutaneous Relapses but High Cure Rate With Doxorubicin-Based Therapy." Journal of Clinical Oncology 19, no. 2 (January 15, 2001): 398–405. http://dx.doi.org/10.1200/jco.2001.19.2.398.
Full textAbstract:
PURPOSE: Establish frequency, presenting features, response and relapse patterns, and outcome of primary cutaneous non-Hodgkin’s lymphoma (PCNHL). PATIENTS AND METHODS: Review of untreated patients, older than 16 years, presenting between 1971 and 1993 with cutaneous lymphoma, not mycosis fungoides, and Ann Arbor stage I. RESULTS: We identified 46 patients, 27 males, with median age of 57 years. Treatment was radiotherapy in 10 patients, doxorubicin-based therapy in 33 patients that was followed by radiotherapy in 25 patients, and other combination with radiotherapy in one patient. The complete response rate was 95%. After a median follow-up of 140 months (range, 61 to 284 months), 18 patients have relapsed, and 14 have died from lymphoma. The first failure was exclusively cutaneous in 50% of relapses. For the 44 treated patients, progression-free survival (PFS; actuarial ± SE) was 61% ± 7% and survival was 58% ± 9% at 12 years. For the 18 patients with diffuse large B-cell lymphoma, after doxorubicin-based regimens, PFS was 71% ± 12% (P = .0003) versus 0% after radiotherapy; survival was 77% ± 12% versus 25% ± 22% (P = 004), respectively. For the nine patients with follicular center-cell lymphoma treated with combined modality, the 12-year PFS was 89% ± 11% and survival 70% ± 18%. CONCLUSION: PCNHL is rare, and its first relapse is exclusively cutaneous in 50% of patients. Patients with diffuse large B-cell lymphoma are curable with doxorubicin-based regimens but not with radiotherapy. Prospective studies in PCNHL should define the cytogenetics, the basis for cutaneous tropism, the prognosis of histologic subtypes, and the role of radiotherapy.
15
Benton, Melissa J., Maura C. Schlairet, and David R. Gibson. "Change in Quality of Life Among Breast Cancer Survivors After Resistance Training: Is There an Effect of Age?" Journal of Aging and Physical Activity 22, no. 2 (April 2014): 178–85. http://dx.doi.org/10.1123/japa.2012-0227.
Full textAbstract:
To evaluate the effect of age on quality of life (QOL) in breast cancer survivors after resistance training, 20 women were assigned to 1 of 2 groups based on age (YRT 40–59 yr, ORT 60–80 yr). Both groups completed 3 sets of 8 exercises twice a week for 8 wk. Measurements were obtained before and after the training program. QOL was measured using the Body Image and Relationship Scale (BIRS). Both groups improved in chest press (p< .001), leg press (p< .001), arm curls (p< .05), and chair stands (p< .001). For QOL, YRT reported greater improvements compared with ORT in BIRS total score (Group × Time interaction,p= .002) and strength and health subscale score (Group × Time interaction,p= .001), and greater age was related to greater perceived impairment (BIRS total:r= .61,p= .004; strength and health subscale:r= .69,p= .001). Despite significant improvements in strength and function, older women perceived relatively little improvement in QOL compared with younger women, and age had a differential negative influence on improvements in QOL.
16
Pigioni, Vanessa Batista, Camila Sanches Manca, Paula Garcia Chiarello, and Juliana Maria Faccioli Sicchieri. "Nutritional Profile of Oncology Patients from an Outpatient Nutritional Service in Brazil." Journal of Nutritional Oncology 5, no. 4 (November 15, 2020): 170–75. http://dx.doi.org/10.34175/jno202004003.
Full textAbstract:
Objective To characterize the nutritional variables of patients referred to an outpatient oncology nutrition service. Methods The electronic medical records of patients diagnosed with malignant neoplasms were analyzed for several parameters: weight loss, body mass index (BMI), hand-grip strength (HGS), fat-free mass index (FFMI) and serum C-reactive protein (CRP). Statistical methods included Pearson’s correlation (significance was set at P ≤ 0.05). Results There was a high prevalence of malnutrition (44%, n = 28) and sarcopenia (61%, n = 23) and a relatively low prevalence of cachexia (13%, n = 6). Moderate positive correlations were observed between the tumor site and CRP level, correlation r = 0.328 (P = 0.026); the tumor site and BMI (r = 0, P = 0.001); FFMI and BMI (r = 0.606, P = 4.334056e-005) and CRP and weight loss (r = 0.355, P = 0.024). There were negative correlations between the tumor staging and BMI r = -0.409, P = 0.001) and weight loss and FFMI (r = -0.467, P = 3,228325e-004). Conclusion These preliminary findings may help institutions implement nutritional approaches, such as the adoption of a line-ofcare focused on nutrition in the department of oncology.
17
Cahn, JY, M. Labopin, F. Mandelli, AH Goldstone, K. Eberhardt, J. Reiffers, A. Ferrant, I. Franklin, P. Herve, and A. Gratwohl. "Autologous bone marrow transplantation for first remission acute myeloblastic leukemia in patients older than 50 years: a retrospective analysis of the European Bone Marrow Transplant Group." Blood 85, no. 2 (January 15, 1995): 575–79. http://dx.doi.org/10.1182/blood.v85.2.575.575.
Full textAbstract:
Abstract High-dose chemotherapy, with or without radiotherapy, followed by autologous stem-cell rescue is used increasingly for the intensification of first remission in acute myeloblastic leukemia (AML). However, these treatments have been limited to young patients due to the increased risks of regimen-related toxicities and mortality with age. Several investigators have recently published the upper age limit for autologous bone marrow transplant (ABMT) in AML because of encouraging results. The results of ABMT for AML were studied in 111 patients > or = 50 years of age intensified in first remission. Median age at transplant was 53 years (range, 50 to 63 years). Fifty patients were conditioned with total body irradiation and 61 with polychemotherapy: 23 with busulfancyclophosphamide, 11 with the University College Hospital (UCH; London, UK) regimen, 6 with BAVC, and 21 with various other treatments. Marrow was purged in only 11 cases. Results were compared with 786 ABMTs performed for AML in patients between 16 and 49 years of age (median, 35 years). For AML in first remission, the probability of leukemia-free survival (LFS) at 4 years was 34% +/- 5% for patients aged 50 years or more and 43% +/- 2% for patients less than 50 years of age (P = .004), with a survival probability of 35% +/- 6% and 48% +/- 2%, respectively (P = .004). The probability of relapse was not significantly different between the two groups (52% +/- 7% v 50% +/- 2%), but transplant-related mortality was significantly higher in the older age group (28% +/- 5% v 14% +/- 2%; P < .0001) and mainly due to infectious complications. In a multivariate analysis, age less than 50 years was a favorable risk factor for LFS, treatment-related mortality (TRM), and survival but not for relapse incidence. These data suggest that ABMT should be considered in older AML patients.
18
Cahn, JY, M. Labopin, F. Mandelli, AH Goldstone, K. Eberhardt, J. Reiffers, A. Ferrant, I. Franklin, P. Herve, and A. Gratwohl. "Autologous bone marrow transplantation for first remission acute myeloblastic leukemia in patients older than 50 years: a retrospective analysis of the European Bone Marrow Transplant Group." Blood 85, no. 2 (January 15, 1995): 575–79. http://dx.doi.org/10.1182/blood.v85.2.575.bloodjournal852575.
Full textAbstract:
High-dose chemotherapy, with or without radiotherapy, followed by autologous stem-cell rescue is used increasingly for the intensification of first remission in acute myeloblastic leukemia (AML). However, these treatments have been limited to young patients due to the increased risks of regimen-related toxicities and mortality with age. Several investigators have recently published the upper age limit for autologous bone marrow transplant (ABMT) in AML because of encouraging results. The results of ABMT for AML were studied in 111 patients > or = 50 years of age intensified in first remission. Median age at transplant was 53 years (range, 50 to 63 years). Fifty patients were conditioned with total body irradiation and 61 with polychemotherapy: 23 with busulfancyclophosphamide, 11 with the University College Hospital (UCH; London, UK) regimen, 6 with BAVC, and 21 with various other treatments. Marrow was purged in only 11 cases. Results were compared with 786 ABMTs performed for AML in patients between 16 and 49 years of age (median, 35 years). For AML in first remission, the probability of leukemia-free survival (LFS) at 4 years was 34% +/- 5% for patients aged 50 years or more and 43% +/- 2% for patients less than 50 years of age (P = .004), with a survival probability of 35% +/- 6% and 48% +/- 2%, respectively (P = .004). The probability of relapse was not significantly different between the two groups (52% +/- 7% v 50% +/- 2%), but transplant-related mortality was significantly higher in the older age group (28% +/- 5% v 14% +/- 2%; P < .0001) and mainly due to infectious complications. In a multivariate analysis, age less than 50 years was a favorable risk factor for LFS, treatment-related mortality (TRM), and survival but not for relapse incidence. These data suggest that ABMT should be considered in older AML patients.
19
Tawfik, Ossama W., Brandan Kramer, Barbara Shideler, Marsha Danley, Bruce F. Kimler, and Jeffrey Holzbeierlein. "Prognostic Significance of CD44, Platelet-Derived Growth Factor Receptor α, and Cyclooxygenase 2 Expression in Renal Cell Carcinoma." Archives of Pathology & Laboratory Medicine 131, no. 2 (February 1, 2007): 261–67. http://dx.doi.org/10.5858/2007-131-261-psocpg.
Full textAbstract:
Abstract Context.—Pathologic stage is the main prognostic factor for predicting outcome in renal cell carcinoma (RCC). Because of its unreliability in predicting tumor progression, other factors are needed to provide additional prognostic information. Objective.—The expression of CD44, cyclooxygenase 2, and platelet-derived growth factor receptor α (PDGFR-α) was evaluated as a potential prognostic factor for survival in patients with RCC. Design.—Sixty-two patients (42 men and 20 women; median age, 61 years), undergoing partial (10 cases) or radical (55 cases) nephrectomy for RCC were retrospectively analyzed by immunohistochemical analysis for CD44, cyclooxygenase 2, and PDGFR-α expression. Impact of various factors on disease-specific and overall survival was calculated using Cox proportional hazards models. Results.—There was a gradual increase in CD44 and cyclooxygenase 2 expression with increasing RCC nuclear grade. In contrast, PDGFR-α expression showed no consistent relationship with nuclear grade. On univariate analysis, metastasis at time of surgery (P < .001), tumor size (P = .004), pathologic stage group (P = .001), and nuclear grade (P = .004) were correlated with disease-specific survival. On multivariate analysis, only the presence of metastasis at diagnosis (P < .001) was significant. For overall survival, metastasis (P < .001), tumor size (P = .02), pathologic stage group (P = .01), nuclear grade (P = .003), and PDGFR-α (P = .03) were significant on univariate analysis. Only metastasis (P = .001) and PDGFR-α (P = .03) were significant on multivariate analysis. Conclusions.—When combined with other variables, PDGFR-α expression in RCC may provide additional predictive value related to the patient's overall survival. However, CD44 and cyclooxygenase 2 do not seem to be independent prognostic indicators in predicting outcomes for patients with RCC.
20
Hollis, J. L., S. R. Crozier, H. M. Inskip, C. Cooper, K. M. Godfrey, and S. M. Robinson. "Age at introduction of solid foods and feeding difficulties in childhood: findings from the Southampton Women’s Survey." British Journal of Nutrition 116, no. 4 (June 30, 2016): 743–50. http://dx.doi.org/10.1017/s0007114516002531.
Full textAbstract:
AbstractThis study aimed to determine whether age at introduction of solid foods was associated with feeding difficulties at 3 years of age. The present study was carried out using data from the Southampton Women’s Survey (SWS). Women enrolled in the SWS who subsequently became pregnant were followed-up during pregnancy and postpartum, and the offspring have been studied through childhood. Maternal socio-demographic and anthropometric data and child anthropometric and feeding data were collected through interviews and self-administered questionnaires. When the children were 3 years of age, mothers/carers rated six potential child feeding difficulty questions on a four-point Likert scale, including one general question and five specific feeding difficulty questions. Age at introduction of solids as a predictor of feeding difficulties was examined in 2389 mother–child pairs, adjusting for child (age last breast fed, sex, gestation) and maternal characteristics (parity, pre-pregnancy BMI, age, education, employment, parenting difficulties, diet quality). The majority of mothers/carers (61 %) reported some feeding difficulties (general feeding difficulty question) at 3 years of age, specifically with their child eating enough food (61 %), eating the right food (66 %) and being choosy with food (74 %). Children who were introduced to solids ≥6 months had a lower risk of feeding difficulties (RR 0·73; 95 % CI 0·59, 0·91, P=0·004) than children who were introduced to solids between 4 and 6 months. No other significant associations were found. There were few associations between feeding difficulties in relation to age at introduction of solid foods. However, general feeding difficulties were less common among infants introduced to solid foods ≥6 months of age.
21
FRANZETTI, F., B. BORGHI, F. RAIMONDI, and V. D. ROSENTHAL. "Impact on rates and time to first central vascular-associated bloodstream infection when switching from open to closed intravenous infusion containers in a hospital setting." Epidemiology and Infection 137, no. 7 (January 15, 2009): 1041–48. http://dx.doi.org/10.1017/s095026880800174x.
Full textAbstract:
SUMMARYAn open-label, prospective cohort, active healthcare-associated infection surveillance sequential study was conducted in four Italian intensive-care units. The aim was to determine the effect of switching from open (glass) to closed fully collapsible plastic intravenous (i.v.) infusion containers (Viaflo®) on rate and time to onset of central venous catheter-associated bloodstream infections (CVC-BSI). A total of 1173 adult patients were enrolled. The CVC-BSI rate during the open container period was significantly higher than during the closed container period (8·2vs. 3·5 BSI/1000 CVC days, relative risk 0·43, 95% confidence interval 0·22–0·84,P=0·01). The probability of developing a CVC-BSI was assessed over time comparing open and closed i.v. infusion containers. In the closed container period, it remained fairly constant (0·8% at days 1–3 to 1·4% at days 7–9) whereas during the open container period it increased (2% at days 1–3 to 5·8% at days 7–9). Overall, the chance of acquiring a CVC-BSI significantly decreased by 61% in the closed container period (Cox proportional hazard ratio 0·39,P=0·004).
22
Steuber, C. P., C. Civin, J. Krischer, S. Culbert, A. Ragab, F. B. Ruymann, Y. Ravindranath, B. Leventhal, R. Wilkinson, and T. J. Vietti. "A comparison of induction and maintenance therapy for acute nonlymphocytic leukemia in childhood: results of a Pediatric Oncology Group study." Journal of Clinical Oncology 9, no. 2 (February 1991): 247–58. http://dx.doi.org/10.1200/jco.1991.9.2.247.
Full textAbstract:
Two hundred fifty-six children with previously untreated acute nonlymphocytic leukemia (ANLL) were evaluated on a Pediatric Oncology Group (POG) phase III randomized trial of both induction and continuation chemotherapies. Induction therapy compared vincristine, cytarabine, and dexamethasone (VADx) with daunorubicin, cytarabine, and thioguanine (DAT). The complete remission (CR) rate using DAT was superior (82% v 61%, P = .02). Postremission therapy consisted of either "standard" two-cycle therapy or a more intensive four-cycle regimen given for 2 years. Overall, there was no difference in outcome for patients randomized to either continuation regimen. The overall complete continuous remission rate (CCR) for the "best" induction/continuation therapy combination at 2 years was .50 (SE = .06), at 3 years was .35 (.04), and at 4 years was .34 (.05). Analysis of selected clinical and laboratory parameters demonstrated differences in induction responses favoring DAT induction but did not impact eventual disease-free survival. There were two subgroups of patients who responded better to four-cycle continuation therapy. These were patients with French-American-British (FAB) M1/M2 (2-year CCR was .20 v .44, P = .01) and patients older than 10 years at diagnosis (.32 v .62, P = .004).
23
Wang, Fei, Christina Marsack-Topolewski, Rosanne DiZazzo-Miller, and Preethy Samuel. "Health of Aging Families: Comparing Compound and Noncompound Caregivers." Innovation in Aging 5, Supplement_1 (December 1, 2021): 104. http://dx.doi.org/10.1093/geroni/igab046.397.
Full textAbstract:
Abstract Providing care to a family member with disabilities takes a toll on the caregiver and the whole family's health. Among aging caregivers, compound caregiving (i.e., caring for additional family members) has become an increasingly common scenario. However, few research studies have focused on compound caregivers. Extant literature describes individual-level outcomes, with sparse knowledge on family-level outcomes. The present study examines the differences in the individual and family health of aging compound and noncompound caregivers, using the family quality of life framework. Web-based cross-sectional data collected from 112 aging caregivers (i.e., over 50 years) was analyzed using chi-square and independent sample t-tests to examine differences between caregivers. Compound caregivers had worse perceptions of personal health (t = -2.96, p = .004, d = -.61) than noncompound caregivers. In terms of family health, although all caregivers shared similar perceptions on the importance, opportunities, initiative, and stability, compound caregivers had lower attainment (t = -2.64, p = .009, d = -.44) and satisfaction (t = -3.90, p < .001, d = -.73) than noncompound caregivers. Findings have practice implications for identifying caregivers' multiple responsibilities. It is necessary to develop individual and family level programs focused on health promotion and caregiving training.
24
Wulandari, Nurul, Fadhilaturrahmi Fadhilaturrahmi, and Rusdial Marta. "The Improving Mathematical Communication Skills by Using Realistic Mathematical Education (RME) Learning Models in Elementary Schools." Edumaspul: Jurnal Pendidikan 5, no. 2 (October 1, 2021): 205–11. http://dx.doi.org/10.33487/edumaspul.v5i2.1967.
Full textAbstract:
Penelitian ini bertujuan untuk meningkatkan kemampuan komunikasi Matematika siswa kelas IV SDN 004 Pulau, tepatnya pada materi pengolahan data. Penelitian ini dilatarbelakangi oleh rendahnya kemampuan komunikasi Matematika pada siswa kelas IV yang berjumlah 26 orang, 12 orang siswa laki-laki dan 14 orang siswa perempuan. Penelitian ini merupakan penelitian tindakan kelas dimana penerapannya dilaksanakan dalam dua siklus dan setiap siklus terdiri dari dua pertemuan. Teknik pengumpulan data pada penelitian ini menggunakan teknik wawancara, observasi, tes dan dokumentasi. Berdasarkan hasil analisis data dapat diketahui adanya peningkatan dalam kemampuan komunikasi Matematika siswa. Sebelum tindakan, ketuntasan hasil kemampuan komunikasi Matematika siswa hanya 53% dengan kategori sangat kurang. Dalam melaksanakan siklus 1 pertemuan 1, ketuntasan hasil kemampuan komunikasi Matematika siswa mencapai 61% dengan kategori kurang. Pada siklus 1 pertemuan 2 hasil tes kemampuan komunikasi Matematika siswa mencapai 69% dengan kategori cukup. Sedangkan pada siklus 2 pertemuan 1, hasil tes kemampuan komunikasi Matematika siswa mencapai 77% masih dengan kategori kurang. Pada siklus 2 pertemuan 2, hasil tes kemampuan komunikasi Matematika siswa mencapai 84% dengan kategori baik. Dengan demikian dapat disimpulkan bahwa kemampuan komunikasi Matematika siswa dapat ditingkatkan dengan menggunakan model pembelajaran realistic mathematic education.
25
Nemunaitis, John, Robert O. Dillman, Paul O. Schwarzenberger, Neil Senzer, Casey Cunningham, Jodi Cutler, Alex Tong, et al. "Phase II Study of Belagenpumatucel-L, a Transforming Growth Factor Beta-2 Antisense Gene-Modified Allogeneic Tumor Cell Vaccine in Non–Small-Cell Lung Cancer." Journal of Clinical Oncology 24, no. 29 (October 10, 2006): 4721–30. http://dx.doi.org/10.1200/jco.2005.05.5335.
Full textAbstract:
Purpose Belagenpumatucel-L is a nonviral gene-based allogeneic tumor cell vaccine that demonstrates enhancement of tumor antigen recognition as a result of transforming growth factor beta-2 inhibition. Patients and Methods We performed a randomized, dose-variable, phase II trial involving stages II, IIIA, IIIB, and IV non–small-cell lung cancer patients. Each patient received one of three doses (1.25, 2.5, or 5.0 × 107 cells/injection) of belagenpumatucel-L on a monthly or every other month schedule to a maximum of 16 injections. Immune function, safety, and anticancer activity were monitored. Results Seventy-five patients (two stage II, 12 stage IIIA, 15 stage IIIB, and 46 stage IV patients) received a total of 550 vaccinations. No significant adverse events were observed. A dose-related survival difference was demonstrated in patients who received ≥ 2.5 × 107 cells/injection (P = .0069). Focusing on the 61 late-stage (IIIB and IV) assessable patients, a 15% partial response rate was achieved. The estimated probabilities of surviving 1 and 2 years were 68% and 52%, respectively for the higher dose groups combined and 39% and 20%, respectively, for the low-dose group. Immune function was explored in the 61 advanced-stage (IIIB and IV) patients. Increased cytokine production (at week 12 compared with patients with progressive disease) was observed among clinical responders (interferon gamma, P = .006; interleukin [IL] -6, P = .004; IL-4, P = .007), who also displayed an elevated antibody-mediated response to vaccine HLAs (P = .014). Furthermore, positive enzyme-linked immunospot reactions to belagenpumatucel-L showed a correlation trend (P = .086) with clinical responsiveness in patients achieving stable disease or better. Conclusion Belagenpumatucel-L is well tolerated, and the survival advantage justifies further phase III evaluation.
26
Saft, Leonie, Jack Shiansong Li, Peter L. Greenberg, Mikkael A. Sekeres, Guillermo F. Sanz, François Dreyfus, Pierre Fenaux, Arlene S. Swern, Mary M. Sugrue, and Eva Hellstrom-Lindberg. "p53 Mutant Independently Impacts Risk: Analysis of Deletion 5q, Lower-Risk Myelodysplastic Syndromes (MDS) Patients Treated with Lenalidomide (LEN) in the MDS-004 Study." Blood 124, no. 21 (December 6, 2014): 414. http://dx.doi.org/10.1182/blood.v124.21.414.414.
Full textAbstract:
Abstract Introduction: Refined risk-classification of patients (pts) with MDS allows for improved treatment selection for individual pts. The Revised International Prognostic Scoring System (IPSS-R) has recently been validated as a prognostic tool in lower-risk MDS pts with deletion 5q [del(5q)], who were treated with LEN in the MDS-004 study (Sekeres et al. Blood Cancer J 2014; in press). P53 nuclear protein expression, as assessed by immunohistochemistry (IHC), predicted overall survival (OS) and risk of progression to acute myeloid leukemia (AML) in lower-risk MDS pts with del(5q) (Saft et al. Haematologica 2014;99:1041-9). This analysis evaluated the prognostic value of adding p53 IHC to IPSS-R to predict OS and AML progression in pts with lower-risk MDS with del(5q). Methods: In a subset of 85 pts from MDS-004 with bone marrow (BM) biopsies available, p53+ staining (≥ 1% IHC+++ BM cells) was visualized by IHC. Twenty-four pts had missing IPSS-R scores; 1 due to lack of baseline cytogenetic data and 23 because of missing exact BM blast percentage. Thus, 61 pts (42 initially treated with LEN and 19 with placebo) had IPSS-R and p53 IHC data available; 89% of pts in the placebo group crossed over to LEN 5 mg at Week 16. The IPSS-R Very Low and Very High risk groups with < 5 pts were combined with the Low and High risk groups, respectively. AML-free survival (AFS), OS, and time to AML progression within p53 IHC status (p53+ vs p53−), and IPSS-R risk groups were characterized by the Kaplan-Meier method with differences evaluated by the log-rank test. Results: Of 61 pts, 38% were p53+. There was a linear increasing trend in the proportion of pts with p53+ across IPSS-R risk groups from Very Low/Low, Intermediate to High/Very High (29%, 47% and 63%, respectively; Cochran-Armitage trend test P = 0.050). The 3 IPSS-R risk groups significantly predicted AFS and OS (log-rank P < 0.001 for both AFS and OS), but not time to AML progression (P = 0.335). Overall, AFS, OS, and time to AML progression differed significantly between p53+ versus p53− pts (23.9 vs 47.9 months for median AFS, P = 0.003; 27.0 vs 50.6 months for median OS, P = 0.005; and 44.3 months vs not reached [NR] for median time to AML progression,P = 0.003). In the IPSS-R Very Low/Low risk group (n = 38), AFS, OS, and time to AML progression were significantly worse in p53+ versus p53− pts (20.1 vs 63.1 months for median AFS, P = 0.011; 28.4 vs 76.8 months for median OS, P = 0.031; and 65.2 months vs NR for median time to AML progression, P = 0.014). Results for all IPSS-R risk groups in pts with p53 and IPSS-R data are presented in the Figure. The lack of significant differences between p53+ versus p53− pts in the Intermediate and High/Very High risk groups is likely due to the small sample size of these groups. Conclusions: In this exploratory subset analysis of lower-risk MDS pts with del(5q), p53 IHC status in the IPSS-R Very Low/Low risk group significantly impacted AFS, OS, and AML progression. These data support the addition of p53 mutational analysis to prognostic risk assessment which should help inform the selection of appropriate treatment for individual MDS pts with del(5q). These results need to be validated in a large sample set, which will be accomplished as part of the ongoing efforts to include prognostic molecular mutations in future updates of IPSS-R Figure 1 AFS (A), OS (B), and time to AML progression (C) in pts with p53 and IPSS-R data (N = 61) Figure 1. AFS (A), OS (B), and time to AML progression (C) in pts with p53 and IPSS-R data (N = 61) Figure 2 Figure 2. Figure 3 Figure 3. Disclosures Shiansong Li: Celgene Corporation: Employment, Equity Ownership. Greenberg:Celgene: Research Funding; Onconova: Research Funding; GSK: Research Funding; Novartis: Research Funding; KaloBios: Research Funding. Sekeres:Amgen Corp.: Membership on an entity's Board of Directors or advisory committees; Boehringer-Ingelheim Corp.: Membership on an entity's Board of Directors or advisory committees; Celgene Corporation: Membership on an entity's Board of Directors or advisory committees. Dreyfus:Novartis: Honoraria; Celgene: Honoraria. Fenaux:Novartis: Research Funding; Janssen: Research Funding; Celgene: Research Funding. Swern:Celgene: Employment, Equity Ownership. Sugrue:Celgene: Employment, Equity Ownership. Hellstrom-Lindberg:Celgene: Research Funding.
27
Nabhan, Chadi, Michelle Byrtek, Shadi Latta, Keith L. Dawson, Xiaolei Zhou, Brian K. Link, Jonathan W. Friedberg, James R. Cerhan, and Christopher R. Flowers. "Age Differences in Disease Characteristics, Patterns of Care, and Outcomes of Follicular Lymphoma (FL) in the United States (US): Report From the National Lymphocare Study (NLCS)." Blood 120, no. 21 (November 16, 2012): 3708. http://dx.doi.org/10.1182/blood.v120.21.3708.3708.
Full textAbstract:
Abstract Abstract 3708 Background: There are few prospective studies on disease characteristics, patterns of care, response, and outcomes in elderly FL patients (pts) in the US. The NLCS is a Genentech-sponsored prospective multicenter registry study that collects this information without study-specific treatment. We utilized the NLCS database to better understand the impact of age on FL outcome. Patients and Methods: All evaluable pts with FL histology in the NLCS were included except pts with FL plus other lymphoma histology or pts who progressed before first treatment or before being assigned to watchful waiting (WW). Using Pearson Chi-Square tests, associations of age groups (≤60, 61–70, >70) with disease characteristics and overall response (ORR) were examined. Median PFS and OS by treatment regimen were estimated using Kaplan-Meier methods for each age group. Cox proportional hazards regression adjusted for baseline factors (grade, number of nodal sites, LDH, Hgb, stage, performance status (PS), bone marrow (BM) involvement, race, and treatment center type) were used to assess treatment differences in PFS and OS and the significance of age by treatment interactions. Results: Of 2,647 pts, 47% (n=1,254) were ≤60 yrs, 25% (n=666) were 61–70 yrs, and 27% (n=727) were >70 yrs (min age of 22; max of 97). Compared with pts ≤60 yrs, pts 61–70 and >70 were more likely to be white (93% >70, 92% 61–70, and 88% ≤60, P=.02 and .02 respectively), have stage I/II disease (37% >70, 36% 61–70, and 29% ≤60, P=.0008 and .0003), have <5 nodal sites (73% >70, 69% 61–70, and 61% ≤60, P=.001 and <.0001), and have poor-risk FLIPI (53% >70, 51% 61–70, and 15% ≤60, P<.0001 and <.0001). Compared with pts ≤60, elderly pts (>70) were more likely to have FL grade 3 (24% vs 18%, P=.01). While there were no differences in geographic distribution by age, elderly pts were more likely to receive therapy at community practices (86%) versus academic institutions than pts ≤60 (77%, P<.0001) or 61–70 (81%, P=.004). Treatments varied significantly by age (P<.0001). More elderly pts were observed compared to pts ≤60 (23% vs19%). When treated, elderly pts (22%) were more likely to receive rituximab (R) monotherapy compared with patients aged 61–70 (12%) or ≤60 (10%). When chemotherapy alone or plus R was given, elderly pts were less likely to receive anthracyclines (45% vs 65% (61–70) and 68% (≤60)). Among all variables, only grade 3 histology predicted anthracycline use in all age groups. Lack of BM involvement predicted anthracycline use for younger pts (≤60 and 61–70). Of those ≤60, white pts were more likely to receive anthracyclines, and of those 61–70, those with ≥5 nodal sites were more likely to receive anthracyclines. ORRs were similar across age groups receiving similar regimens with R plus chemo providing the highest ORR. Adjusting for baseline factors, treatment (WW, R, R-Chemo, or other) benefit varied for each age group in terms of PFS (P=.02), with treatment outcomes being most differentiated among younger pts (Table). PFS appeared shorter in elderly pts regardless of the treatment received. No significant interaction between age and efficacy of anthracycline in terms of PFS or OS was observed (P-values >.65), but the overall effect of anthracycline for all pts was beneficial for PFS (HR=0.80, P=.02) and OS (HR=0.67, P=.003). Median OS was 8 years for elderly and not reached for others. After adjusting for baseline factors, no significant differences in treatment impact by age on OS were seen. Elevated LDH, reduced Hgb, stage III/IV, PS ≥1, and BM involvement were all significantly associated with shortened OS. These factors were also significantly associated with treatment choice, as worse-prognosis elderly pts were more likely to receive either R or R+chemo than WW or other treatment. Conclusions: FL pts >70 yrs more commonly received R alone and less commonly received anthracyclines when treated with chemotherapy. The impact of anthracyclines on PFS did not vary by age, but differences in PFS for other treatment regimens showed a stronger association among younger pts Disclosures: Nabhan: Genentech: Research Funding, Speakers Bureau. Byrtek:Genentech, Inc., a member of the Riche Group: Employment, Equity Ownership. Dawson:Genentech, Inc., a member of the Riche Group: Employment, Equity Ownership. Link:Genentech, Inc., a member of the Riche Group: Consultancy; Celgene: Consultancy; Spectrum: Consultancy. Friedberg:Genentech: Consultancy. Cerhan:Genentech: National LymphoCare Scientific Advisory Board Other. Flowers:Celgene: Consultancy; Prescription Solutions: Consultancy; Seattle Genetics: Consultancy; Millennium: Consultancy, Research Funding; Genentech: Consultancy; GIlead: Research Funding; Spectrum: Research Funding; Janssen: Research Funding; Lymphoma Research Foundation: Membership on an entity's Board of Directors or advisory committees.
28
ARCHIMÈDE, H., C. PONCET, M. BOVAL, F. NIPEAU, L. PHILIBERT, A. XANDÉ, and G. AUMONT. "Comparison of fresh and dried Digitaria decumbens grass intake and digestion by Black-belly rams." Journal of Agricultural Science 133, no. 2 (September 1999): 235–40. http://dx.doi.org/10.1017/s0021859699006784.
Full textAbstract:
The intake and digestion of fresh and dried Digitaria decumbens grass by rams was compared using a 2×2 factorial design. The experiment took place in Guadeloupe (French West Indies) in 1996. Eight rams (mean liveweight: 45·7±3·1 kg) were maintained in metabolism cages. Digitaria decumbens grass was cut daily and distributed to four of them, the other four were fed the following day with the equivalent forage which had meanwhile been dried for 20 h at 60°C. Chemical composition (g/kg of dry matter (DM)) of the two diets based on neutral detergent fibre (NDF, 713, S.E. 18), acid detergent fibre (ADF, 361, S.E. 13) and crude protein (CP, 90, S.E. 4) was similar. The DM intake (61·0 and 53·2 g/W0·75, S.E. 2·0, P<0·05), the NDF (0·753 and 0·727, S.E. 0·004, P<0·011) and CP (0·588 and 0·544, S.E. 0·014, P<0·09) total tract digestibility of fresh and dried herbage were different. Nylon bag estimates of effective DM degradability and fractional degradation rates (per h) in the rumen were 0·436, 0·414 (S.E. 0·005, P<0·004) and 0·048, 0·038 (S.E. 0·002, P<0·02) for fresh and dried grass, respectively. Rumen digestibility of organic matter and NDF were 0·516, 0·541 (S.E. 0·021) and 0·763, 0·692 (S.E. 0·019), respectively. The rumen turnover rates of particles (per h) were 0·024 and 0·015 (S.E. 0·001, P<0·05) for fresh and dried forage respectively. The efficiency of microbial protein synthesis (g microbial nitrogen/kg organic matter apparently degraded in the rumen) was similar with the two diets : 33·5 and 33·0 (S.E. 3·3, P<0·9) for fresh and dried forage respectively. In conclusion, fresh Digitaria decumbens was nutritionally superior to dried. This is probably due to a faster degradation rate and a lower rumen retention time of the fresh forage.
29
CHUANG, Y. M., S. C. KU, S. J. LIAW, S. C. WU, Y. C. HO, C. J. YU, and P. R. HSUEH. "Disseminated Cryptococcus neoformans var. grubii infections in intensive care units." Epidemiology and Infection 138, no. 7 (October 2, 2009): 1036–43. http://dx.doi.org/10.1017/s0950268809990926.
Full textAbstract:
SUMMARYA retrospective study of clinical characteristics, outcome and prognostic factors of patients with cryptococcosis was undertaken in intensive care units (ICUs) of a medical centre for the period 2000–2005. Twenty-six patients with Cryptococcus neoformans var. grubii infection were identified (16 males, median age 58 years). The most frequent underlying diseases were liver cirrhosis (38·5%), diabetes mellitus (26·9%) and HIV infection (19·2%). The most frequently identified sites of infection were blood (61·5%), cerebrospinal fluid (38·5%) and airways (34·6%). The mean Acute Physiologic and Chronic Health Evaluation II score at ICU admission was 22·46. The ICU mortality rate in these patients was 73·1% (19/26) and there were a further two mortalities recorded after discharge from ICU, reaching a total mortality rate of 80·8% (21/26). Patients with ICU survival >2 weeks had lower rates of HIV infection (P=0·004), less use of inotropic agents during ICU stay (P<0·001) and lower white blood cell counts (P=0·01). After adjusting for clinical variables in the multivariate Cox regression model, diabetes and cryptococcal infection after ICU admission were independent predictors of good long-term prognosis (P=0·015) and HIV infectious status was associated with poor outcome (P=0·012).
30
Luryi, Alexander L., Michael LaRouere, Seilesh Babu, Dennis I. Bojrab, John Zappia, Eric W. Sargent, and Christopher A. Schutt. "Traumatic versus Idiopathic Benign Positional Vertigo: Analysis of Disease, Treatment, and Outcome Characteristics." Otolaryngology–Head and Neck Surgery 160, no. 1 (October 16, 2018): 131–36. http://dx.doi.org/10.1177/0194599818797892.
Full textAbstract:
Objective To compare characteristics between traumatic and idiopathic benign paroxysmal positional vertigo (BPPV) focusing on outcomes. Study Design Retrospective chart review. Setting High-volume tertiary otology center. Subjects and Methods Records of patients with BPPV treated at a single institution from 2007 to 2017 were analyzed. Traumatic BPPV was defined as BPPV symptoms beginning within 30 days following head trauma. Patient, disease, treatment, and outcome characteristics were compared between traumatic and idiopathic BPPV groups. Results A total of 1378 patients with BPPV were identified, 110 (8%) of which had traumatic BPPV. The overall resolution rate was 76%, and the recurrence rate was 38%. Patients with traumatic BPPV were younger (mean age: 61 vs 65 years, P = .007) and more likely to be male (40% vs 27%, P = .004) than patients with idiopathic BPPV. Traumatic BPPV was more likely to affect both ears (32% vs 19%, P = .009). No significant association was detected between trauma history and resolution rate, recurrence rate, number of treatment visits, or affected semicircular canals. Conclusion Patients with traumatic BPPV are more likely to be young and male than those with idiopathic disease. Although traumatic BPPV is often bilateral, outcomes for traumatic BPPV may be similar to those for idiopathic BPPV, contrary to prior reports.
31
Yoneda, Ai, Harumi Wakiyama, Junko Kurihara, and Takashi Kitaoka. "Initial treatment for polypoidal choroidal vasculopathy: Ranibizumab combined with photodynamic therapy or fixed-dosing aflibercept monotherapy." European Journal of Ophthalmology 30, no. 6 (September 2, 2019): 1473–79. http://dx.doi.org/10.1177/1120672119871886.
Full textAbstract:
Purpose: To compare the 2-year outcomes of combination therapy using intravitreal ranibizumab and photodynamic therapy with those of fixed-dosing intravitreal aflibercept monotherapy as initial treatment for treatment-naïve polypoidal choroidal vasculopathy. Methods: We retrospectively reviewed 63 eyes of 61 patients with treatment-naïve polypoidal choroidal vasculopathy who had undergone at least 24 months of follow-up. In total, 43 eyes underwent intravitreal ranibizumab–photodynamic therapy combination therapy and 20 eyes underwent fixed-dosing intravitreal aflibercept monotherapy. Visual outcomes and the number of treatments were compared between the two groups. Results: The mean logarithm of minimal angle of resolution best-corrected visual acuity significantly improved from 0.48 ± 0.41 at baseline to 0.30 ± 0.47 at 24 months in the intravitreal ranibizumab–photodynamic therapy group ( p = .0002) and from 0.30 ± 0.18 at baseline to 0.16 ± 0.18 at 24 months in the intravitreal aflibercept group ( p = .004), with no significant intergroup differences. The mean number of intravitreal ranibizumab or intravitreal aflibercept injections over 24 months was 5.7 ± 4.5 in the intravitreal ranibizumab–photodynamic therapy group and 12.2 ± 3.8 in the intravitreal aflibercept group ( p < .0001). Conclusion: The intravitreal ranibizumab–photodynamic therapy combination therapy was noninferior to fixed-dosing intravitreal aflibercept monotherapy in improving visual acuity and required fewer injections.
32
Hung, Chung-Shan, Ching-Hui Loh, Jyh-Gang Hsieh, Jia-Ching Chen, Yan-Wei Lin, and Chia-Feng Yen. "The Potential Win-win Strategy for Healthy Aging and Environmental Protection: Environmental Volunteering." American Journal of Health Promotion 36, no. 3 (November 6, 2021): 510–13. http://dx.doi.org/10.1177/08901171211055599.
Full textAbstract:
Purpose To explore the physical activity level of community environmental volunteering (CEV) participants and the differences in physical functions and daily activity patterns between the older adults who engaged in intensive CEV (≥15 hours/week) and non-intensive CEV (<15 hours/week) groups. Design Cross-sectional study. Setting Three recycling stations in Taiwan. Sample In total, 113 community-dwelling older adults who regularly participated in CEV. The response rate was 53%. Measures The ActiGraph wGT3x-BT accelerometer for the percentage of sedentary, light, and moderate to vigorous physical activity (MVPA) of CEV time and awaken time; the Jamar hand dynamometer for grip strength; and the MicroFET3 muscle testing dynamometer for knee extension strength. Analysis Analysis of covariance with the baseline characteristics as covariates. Results Overall, MVPA, light, and sedentary activities accounted for 53.73%, 41.10%, and 5.23% of CEV time, respectively. The intensive group (n = 61) displayed greater dominant handgrip strength ( P = .004) and higher MVPA percentage in daily life ( P = .044) than the non-intensive group (n = 52). Conclusion CEV provides sufficient opportunities for older adults to perform physical activity. Intensive CEV is related to greater handgrip strength but not lower limb strength. Further study is needed to establish the causal relationship between CEV and health variates.
33
Roy, Denis-Claude, Johan Maertens, Irwin Walker, Silvy Lachance, Jean Roy, Stephen Ronan Foley, Philippe Lewalle, et al. "Selective Photodepletion of Recipient-Alloreactive T-Cells Enables Safe and Efficacious Haploidentical HSCT: Initial Results from a Phase 2 Trial in Patients with AML, ALL, and MDS." Blood 124, no. 21 (December 6, 2014): 314. http://dx.doi.org/10.1182/blood.v124.21.314.314.
Full textAbstract:
Abstract Introduction For patients in need of a hematopoietic stem cell transplant (HSCT) but lacking an HLA matched donor, a haploidentical family donor is a particularly appealing alternative. However, to prevent graft-versus-host disease (GVHD), haploidentical HSCT necessitates intensive in vivo or ex vivo T-cell depletion that results in frequent and often lethal infectious complications and/or high relapse rates, thus decreasing overall survival. To overcome this limitation, we have developed a strategy that photodepletes host-reactive cells from the donor T cell graft, while preserving anti-infection and anti-leukemia reactivity. Patients and Methods In an open-label, multi-center phase 2 clinical trial (CR-AIR-007; NCT01794299), 12 of a planned 23 patients with high-risk hematologic malignancies were treated to date with this immunotherapy approach consisting of donor lymphocytes selectively allodepleted of host-reactive T-cells using photodynamic therapy (ATIR). ATIR was infused 28-32 days after haploidentical CD34-selected HSCT. No post-transplant GVHD prophylaxis was used. These patients were compared to a control group of 28 patients treated in a previous Phase 2 study with an investigational product manufactured using a process different from the Phase 1 trial and resulting mainly in dead and inactive cells instead of ATIR (CR-AIR-004). Results Twelve patients, mean age of 45 (range 21-64), 6 females/6 males with AML (n=9) and ALL (n=3) were treated with ATIR so far. ATIR consisted mainly of T-cells (>90%), with residual B and NK cells (≤10%). Selective depletion of recipient-reactivity in each ATIR cell graft was assessed using a CFSE-based proliferation assay. Cell division numbers upon stimulation were analyzed using Modfit LT software (Fig 1A), which generated a proliferation index representing viable/reactive T-cells in donor cells (blue) and final ATIR product (green)(Fig 1B). Selective depletion of recipient-reactive T-cells with preservation of reactivity towards 3rd party antigens and anti-CD3/CD28 was observed in all ATIR cell grafts and used as a release criteria in the 007 study. Figure 1: A) CFSE-dilution pattern in Modfit LT software of ATIR stimulated with 3rd party cells. B) CFSE-based proliferation confirmed selective depletion of recipient-reactive T-cells in all grafts (representative depiction). Figure 1:. A) CFSE-dilution pattern in Modfit LT software of ATIR stimulated with 3rd party cells. B) CFSE-based proliferation confirmed selective depletion of recipient-reactive T-cells in all grafts (representative depiction). Preparative regimen consisted of A) FTBI (1200 cGy; n=5) or B) melphalan (120 mg/m2; n=7), along with thiotepa (10 mg/kg), fludarabine (30 mg/m2 x5 d) and ATG (2.5 mg/kg x4 d). Neutrophil and platelet engraftment was achieved in all patients at a median of 12 days (range: 9-35). No patient experienced graft rejection. Patients (n=28) in the 004 control group, mean age of 42 (range 18-61), 13 females/15 males had AML (n=19), ALL (n=6) or MDS (n=3). CFSE proliferation in T-cell grafts could not be assessed a posteriori due to low cell viability. These 004 patients received the same A) FTBI- (n=14), B) melphalan- (n= 10) based preparative regimen as 007 patients, except for 4 patients receiving single fraction (800 cGy) TBI. Neutrophil and platelet engraftment was achieved at a median of 16 days (range: 7-54). Three patients showed secondary graft rejection. Two patients in study CR-AIR-007 developed acute GVHD grade I (skin only) approximately 130 days post HSCT, which was of short duration, (18 and 41 days). Two patients died of infection and no patient relapsed at a mean follow-up of 8 months post HSCT (range 1-14 months). In the CR-AIR-004 control group, 2 patients developed grade I, 1 patient grade II and 3 patients grade III GvHD, none of these cases were lethal. Seventeen patients died of transplant related complications and 2 patients of relapse/disease progression. TRM is 20% in 007 group vs 63% in the 004 control group and OS is 80% in 007 group vs 35% in the 004 control group at 9 months post-transplant (Figures 2A and 2B). Figure 2A Kaplan Meier Transplant Related Mortality: 004 vs 007 (p=0.06) Figure 2B Kaplan Meier Overall Survival (OS): 004 vs 007 (p=0.03) Conclusions These data confirm that a novel immunotherapy strategy consisting of donor lymphocytes selectively photodepleted of alloreactive cells (ATIR) can be manufactured consistently and reproducibly. Results to date show that ATIR is safe and does not cause any grade III/IV GvHD. Moreover, haploidentical HSCT patients treated with ATIR demonstrate very promising TRM and OS rates when compared to the control group. Disclosures Roy: Kiadis Pharma: Consultancy, Research Funding. Foley:Hoffman-LaRoche: Advisory Board/Lectures Other, Honoraria; Lundbeck: Advisory Board/Lectures, Advisory Board/Lectures Other, Honoraria; Sanofi: Advisory Board/Lectures, Advisory Board/Lectures Other, Honoraria; Celgene: Advisory Board/Lectures, Advisory Board/Lectures Other, Honoraria; Pfizer: Advisory Board/Lectures Other, Honoraria; Novartis: Advisory Board/Lectures Other, Honoraria; Jansen: Advisory Board/Lectures Other, Honoraria; Alexion: Advisory Board/Lectures, Advisory Board/Lectures Other, Honoraria; Roche Canada: Honoraria, Research Funding, Unrestricted educational grant, Unrestricted educational grant Other. De Jong:Kiadis Pharma: Employment. Velthuis:Kiadis Pharma: Employment. Gerez:Kiadis Pharma: Employment. Reitsma:Kiadis Pharma: Employment. Wagena:Kiadis Pharma: Employment.
34
HUSSEIN, N. R., I. TUNJEL, Z. BASHARAT, A. TAHA, and W. IRVING. "The treatment of HCV in patients with haemoglobinopathy in Kurdistan Region, Iraq: a single centre experience." Epidemiology and Infection 144, no. 8 (December 9, 2015): 1634–40. http://dx.doi.org/10.1017/s0950268815003064.
Full textAbstract:
SUMMARYVarious variables that might influence the rapid and sustained virological response to recombinant PEG-IFN-α-2a were explored in Iraqi HCV-infected patients with haemoglobinopathy. Forty-three patients were evaluated for the relationship between rapid virological response (RVR), IL-28B polymorphism, viral load, liver enzyme levels, blood group, ultrasound findings, or HCV genotype and the sustained virological response (SVR) achievement. The overall RVR was 55·81% while the overall SVR was 53·49%. SVR in patients that achieved RVR was 82·61% (P = 0·0004). A significant association was found between initial alanine transaminase levels and viral load with SVR achievement (P = 0·025) and (P = 0·004), respectively. Thirty-two (74%) out of 43 of our samples were host genotyped at the IL-28B locus as CC, a significant association was found between CC group and SVR achievement (P = 0·04). Of our samples, 23/43 (53%) were typed as HCV genotype 4, 10/43 (23%) as genotype 1, 9/43 (20·9%) as genotype 3 and 1/43 (2·3%) as genotype 2. A significant association was found between genotype 3 and SVR achievement (P = 0·006). Multivariate analysis showed that only RVR achievement independently associated with SVR in the Iraqi population (P = 0·00). These results can be used to classify the patients requiring the more expensive new direct-acting antiviral drugs.
35
Cecen, Sare, Ali A. Yavuz, Yigit Cecen, Evrim Duman, Beyza S. Ozdemir, and Melek G. Aksu. "Effect of LINAC-based postoperative radiotherapy on local control and survival in patients with non-small cell lung cancer." Journal of Radiotherapy in Practice 16, no. 2 (January 18, 2017): 171–76. http://dx.doi.org/10.1017/s1460396916000558.
Full textAbstract:
AbstractAimTo perform a retrospective analysis of survival, local–regional control and the effect of prognostic factors in 61 non-small cell lung cancer patients who were treated with postoperative radiotherapy (PORT) by a linear accelerator (LINAC).Material and methodsA total of 50–66 Gy PORT with a fractional dose of 1·8–2 Gy was administered to 24 patients (24·5%) for surgical margin positivity, 33 patients (54%) for mediastinal lymph node involvement and 13 patients (21·5%) for both mediastinal lymph node involvement and positive surgical margins.ResultsMedian follow-up was 17 months, and the median survival and median distant metastasis-free survival were 25 and 19 months, respectively. Local-regional progression was observed in 10 patients (16·4%). Treatment modality (2D/3D) (p=0·021), tumour size >4 cm (p=0·004), surgical margin positivity (p=0·001), and left lung localisation of the tumour (p≤0·05) were the prognostic factors in terms of survival.ConclusionsA survey of the literature shows that, without PORT, local recurrence or progression rates increase while overall survival rates decrease. In this study, only patients with PORT are studied and the results show that the local progression and overall survival rates are comparable with literature of LINAC-based PORT. In the case of overall survival, 3D treatment shows better results than 2D treatment modality.
36
Herman, Gidon, Oren Nakdimon, Pazit Levinger, and Shmuel Springer. "Agreement of an Evaluation of the Forward-Step-Down Test by a Broad Cohort of Clinicians With That of an Expert Panel." Journal of Sport Rehabilitation 25, no. 3 (August 2016): 227–32. http://dx.doi.org/10.1123/jsr.2014-0319.
Full textAbstract:
Context:The forward-step-down (FSD) test may be used to identify underlying pathologies related to lower-extremity injuries. However, research on its interrater reliability is limited.Objective:To assess the interrater reliability of the FSD test with a broad cohort of clinicians and to compare the level of agreement with an expert panel.Design:Single-measure, interrater reliability.Setting:Annual conference of the Israeli Physical Therapy Society.Participants:15 healthy subjects who performed the FSD test and 142 physical therapists (PTs) who evaluated performance.Methods:Each subject performed the FSD while being videoed. Six videos were selected by an expert panel for analysis. After viewing the videos, FSD performance was rated by 142 PTs, as well as by the expert panel, using a 3-level scale.Main Outcome Measures:Interrater reliability determined by intraclass correlation coefficient (ICC) and percentage of agreement with the expert panel.Results:Fair to good reliability and acceptable agreement were found for the entire sample of raters (ICC –.61, agreement 74%). The percentage of agreement was greater in the subgroup of raters who were familiar with the FSD than in those who were not (78.08% vs 69.32%, respectively, P = .004). Years of work experience did not affect the percentage of agreement (P = .141).Conclusions:Fair to good interrater reliably of the FSD test was demonstrated by a broad cohort of PTs. The findings support the clinical utility of the FSD test as an assessment tool for quality of movement.
37
Slayday, Riki, Tyler Bell, Michael Lyons, William Kremen, and Carol Franz. "Erectile Function, Sexual Satisfaction, and Cognitive Decline in Men from Midlife to Old Age." Innovation in Aging 5, Supplement_1 (December 1, 2021): 1002. http://dx.doi.org/10.1093/geroni/igab046.3595.
Full textAbstract:
Abstract We investigated how changes in erectile function and sexual satisfaction relate to cognitive decline in men from midlife into early old age. This is a major transitional period for increased incidence of erectile function and for cognitive decline. We examined 833 men from the Vietnam Era Twin Study of Aging whose mean ages were 56, 61, and 68 at the time of assessment. Erectile function and sexual satisfaction were measured using scores from the International Index of Erectile Function. Individuals with erectile dysfunction at baseline were excluded. Cognitive performance was measured using factor scores for separate domains of episodic memory, executive function, and processing speed. We tested linear mixed models hierarchically adjusted for demographics, sexual activity, as well as physical and mental health confounders to examine how changes in erectile function and sexual satisfaction related to changes in cognitive function. Declines in erectile function were associated with declines in episodic memory (p=.004, d=.25), while declines in sexual satisfaction were associated with declines in processing speed (p=.006, d=.19). Decreasing erectile function and sexual satisfaction may be indicative of individuals also likely to be facing cognitive decline. Possible mechanisms accounting for these changes may include white matter microvascular disease and/or various lifestyle influences. Discussing and tracking sexual health with middle aged men may be a crucial step in identifying those likely to face cognitive decline.
38
Visconte, Valeria, Ali Tabarroki, Edy Hasrouni, Yang Liu, Betty K. Hamilton, Craig A. Portell, Edward A. Copelan, Anjali Advani, Mikkael A. Sekeres, and Ramon V. Tiu. "Patients with SF3B1 Mutation Have Good Prognosis Even in the Presence of Other Poor Prognostic MDS Features and Have Better Outcomes During Treatment with Low Intensity Chemotherapy." Blood 120, no. 21 (November 16, 2012): 3831. http://dx.doi.org/10.1182/blood.v120.21.3831.3831.
Full textAbstract:
Abstract Abstract 3831 The discovery of mutations in components of the RNA splicing machinery has underlined the importance of this pathogenetic mechanism in MDS biology. We and others reported that mutations in SF3B1 are frequent in refractory anemia with ring sideroblasts (RARS) and RARS associated with thrombocytosis (RARS-T). We recently reported good survival outcomes in a large cohort of SF3B1 mutant patients similar to the findings of Papaemmanuil et al, NEJM< 2011. Here, we aimed to evaluate the correlation between SF3B1 mutations in association with other poor prognostic clinical and pathologic factors in MDS. We focused on a large cohort of patients with several myeloid malignancies (n=340). Patients were grouped in MDS (n=176), MDS/MPN (n=88) and secondary AML (sAML) from a previous MDS (n=76). Diseases were classified according to the 2008 WHO classification. Survival outcomes (overall survival [OS], progression free survival [PFS] and event free survival [EFS]) were defined according to MDS IWG criteria. We studied a total of 340 patients with myeloid malignancies. median age, 69 years old (range 19–92), sex (Male, n=222; females, n=118). We performed direct sequencing for SF3B1 (exon 13–16) on a large cohort of MDS, MDS/MPN and sAML patients and found 11.8% SF3B1 mutants. The outcomes of SF3B1 mutant vs WT patients were compared based on the presence of poor clinicopathologic factors associated with MDS like RBC transfusion dependence, presence of SNP-A lesions, presence of acquired somatic uniparental disomy (AS-UPD), Age ≥ 60 years, presence of reticulin fibrosis in the bone marrow. We also assessed the effects of therapies in the prognostic effect of SF3B1 mutations. We previously reported that the presence of new SNP-A lesions in myeloid malignancies including MDS and AML are associated with poor prognostic outcomes. However, the good prognostic effects of SF3B1 mutation is still apparent even in the patients with new SNP-A abnormalities (OS: 40 vs 16 mos, p=.003; PFS: 40 vs 10 mos, p=.003, 40 vs 10 mos, p=.0007. However, when analysis is limited to acquired somatic uniparental disomy defects which we recently reported as the worst lesion among SNP-A abnormalities, the good prognostic effect of SF3B1 is lost (OS: 19 vs 9 mos, p=.29, PFS: 18 vs 7 mos, p=.20, EFS: 19 vs 8 mos, p=.17). Age is an important predictor of outcomes in MDS with higher age associated with worse outcomes. SF3B1 remained predictive of good outcomes in patients ≥ 60 years of age (OS: 40 vs 16, p=.002; PFS: 40 vs 11 mos, p=.003; EFS: 40 vs 10 mos, p=.0005). Persistent RBC transfusions are also associated with inferior survival in MDS, yet SF3B1 mutant patients continued to have good outcomes (OS 34 vs 13, p=.002; PFS: 27 vs 8 mos, p=.004; EFS: 14 vs 9 mos, p=.001). Reticulin fibrosis in the bone marrow is a characteristic feature of myeloproliferative neoplasms but their presence in MDS is associated with unfavorable results, SF3B1 mutant retain their good outcomes even in the presence of reticulin fibrosis in the BM (OS: 40 vs 15 mos, p=.09; PFS: 47 vs 12 mos, p=.04; EFS: 75 vs 13 mos, p=.008). Patients screened for SF3B1 were also further stratified according to treatments received. No patients with SF3B1 mutations underwent allogeneic hematopoietic stem cell transplantation and high intensity chemotherapy specifically induction chemotherapy or high dose cytarabine. However based on treatment with LIC, SF3B1 mutant patients have better survival outcomes compared to WT patients (OS: 61 vs 17 mos, p=.004; PFS: not reached [NR] vs 7 mos; p=.009; EFS: 61 vs 10 mos, p=.001). These observed survival outcomes remain significant when patients were stratified according to disease subtypes. MDS and MDS/MPN patients treated with LIC have better outcomes if they have SF3B1 mutation (OS: 61 vs 23 mos, p=.005; PFS: NR vs 16 mos, p=.01; EFS: 61 vs 16 mos, p=.001). A high number of TET2/DNMT3A mutations are found in SF3B1 mutants. TET2/DNMT3A mutations have been previously association with improved response to hypomethylating agents which is one of the possible reasons why SF3B1 mutants treated with LIC did better than their WT counterpart. In conclusion, SF3B1 retains its favorable prognostic effect even in the face of poor prognostic factors such as RBC transfusion dependence, presence of SNP-A lesions, Age ≥ 60 years, presence of reticulin fibrosis in the bone marrow except in the presence of AS-UPD. SF3B1 mutants treated with LIC also have better outcomes. Disclosures: No relevant conflicts of interest to declare.
39
Hahn, Thomas, Hans-Dieter Carl, Andreas Jendrissek, Matthias Brem, Bernd Swoboda, Philipp Rummel, and Johannes Pauser. "Assessment of Plantar Pressure in Hindfoot Relief Shoes of Different Designs." Journal of the American Podiatric Medical Association 104, no. 1 (January 1, 2014): 19–23. http://dx.doi.org/10.7547/0003-0538-104.1.19.
Full textAbstract:
Background Although there are several different concepts of hindfoot relief footwear, there are no studies on the extent of pressure reduction to be achieved by this footwear. Therefore, we sought to evaluate the reduction in plantar pressure to be achieved with two different hindfoot relief shoes. Methods Ten healthy volunteers performed three trials at a self-selected speed. Peak pressure values in mass-produced shoes (normal gait) were considered as 100% and were compared with measurements in two differently designed hindfoot relief shoes. Foot portions were defined as heel (0%–15% of total insole length), hindfoot (16%–30%), midfoot (31%–60%), and forefoot (61%–100%). Results Heel and hindfoot peak pressures were significantly reduced in both shoes compared with normal gait (P < .05), but the extent of peak pressure reduction under the heel and hindfoot varied significantly between the tested shoes. Midfoot peak pressure was not significantly reduced in tested shoes compared with baseline (P > .05) but differed significantly between the two shoes. Forefoot peak pressure was significantly reduced with one of the tested shoes (to a median 73% baseline; P = .004) but not with the other (median, 88% baseline). Conclusions Hindfoot relief shoes leave a considerable amount of peak pressure, predominantly under the hindfoot. The extent of peak pressure reduction for the heel and the hindfoot varies between different hindfoot relief shoes. Depending on the affected foot area, the kind of hindfoot relief shoe should be carefully chosen.
40
Mais, Laís Amaral, Sarah Warkentin, Juliana Bergamo Vega, Maria do Rosário Dias de Oliveira Latorre, Susan Carnell, and José Augusto de Aguiar Carrazedo Taddei. "Sociodemographic, anthropometric and behavioural risk factors for ultra-processed food consumption in a sample of 2–9-year-olds in Brazil." Public Health Nutrition 21, no. 1 (October 9, 2017): 77–86. http://dx.doi.org/10.1017/s1368980017002452.
Full textAbstract:
AbstractObjectiveThe present study aimed to identify food patterns among 2–9-year-olds and investigate sociodemographic, anthropometric and behavioural predictors of less healthy dietary patterns.DesignCross-sectional study. Parents of 2–9-year-olds completed an FFQ and factor analysis was applied to identify dietary patterns. Parents also completed questionnaires assessing sociodemographic, anthropometric and behavioural characteristics of parents and children, including parental feeding practices.SettingParticipants were recruited from private schools of Campinas and São Paulo, SP, Brazil, between April and June 2014.SubjectsParents of 2–9-year-olds (n 929).ResultsTwo dietary patterns emerged: ‘traditional food’ and ‘ultra-processed food’. Lower maternal education (OR=2·05, P=0·010) and higher maternal weight status (OR=1·43, P=0·044) were associated with a greater likelihood of the ultra-processed food pattern. Lower perceived parental responsibility for adequacy of food group intake (OR=2·41, P=0·020), and lower scores on the parental feeding practices of ‘Healthy Eating Guidance’ (OR=1·83, P<0·001) and ‘Monitoring’ (OR=2·52, P<0·001), were also associated with the presence of this pattern, as was higher child’s screen use during mealtimes (OR=1·61, P=0·004).ConclusionsThe present study is the first to evaluate associations between less healthy dietary patterns of Brazilian 2–9-year-olds and parental feeding practices. Our findings highlight sociodemographic, anthropometric and behavioural factors within families that could be used to target tailored policies to at-risk populations.
41
Zhitova, Elena S., Igor V. Pekov, Ilya I. Chaikovskiy, Elena P. Chirkova, Vasiliy O. Yapaskurt, Yana V. Bychkova, Dmitry I. Belakovskiy, et al. "Dritsite, Li2Al4(OH)12Cl2·3H2O, a New Gibbsite-Based Hydrotalcite Supergroup Mineral." Minerals 9, no. 8 (August 17, 2019): 492. http://dx.doi.org/10.3390/min9080492.
Full textAbstract:
Dritsite, ideally Li2Al4(OH)12Cl2·3H2O, is a new hydrotalcite supergroup mineral formed as a result of diagenesis in the halite−carnallite rock of the Verkhnekamskoe salt deposit, Perm Krai, Russia. Dritsite forms single lamellar or tabular hexagonal crystals up to 0.25 mm across. The mineral is transparent and colourless, with perfect cleavage on {001}. The chemical composition of dritsite (wt. %; by combination of electron microprobe and ICP−MS; H2O calculated by structure refinement) is: Li2O 6.6, Al2O3 45.42, SiO2 0.11, Cl 14.33, SO3 0.21, H2Ocalc. 34.86, O = Cl − 3.24, total 98.29. The empirical formula based on Li + Al + Si = 6 apfu (atom per formula unit) is Li1.99Al4.00Si0.01[(OH)12.19Cl1.82(SO4)0.01]Σ14.02·2.60(H2O). The Raman spectroscopic data indicate the presence of O–H bonding in the mineral, whereas CO32– groups are absent. The crystal structure has been refined in the space group P63/mcm, a = 5.0960(3), c = 15.3578(13) Å, and V = 345.4(5) Å3, to R1 = 0.088 using single-crystal data. The strongest lines of the powder X-ray diffraction pattern (d, Å (I, %) (hkl)) are: 7.68 (100) (002), 4.422 (61) (010), 3.832 (99) (004, 012), 2.561 (30) (006), 2.283 (25) (113), and 1.445 (26) (032). Dritsite was found as 2H polytype, which is isotypic with synthetic material and shows strong similarity to chlormagalumite-2H. The mineral is named in honour of the Russian crystallographer and mineralogist Prof. Victor Anatol`evich Drits.
42
Griffiths, Alys W., Christopher P. Albertyn, Natasha L. Burnley, Byron Creese, Rebecca Walwyn, Ivana Holloway, Jana Safarikova, and Claire A. Surr. "Validation of the Cohen-Mansfield Agitation Inventory Observational (CMAI-O) tool." International Psychogeriatrics 32, no. 1 (April 10, 2019): 75–85. http://dx.doi.org/10.1017/s1041610219000279.
Full textAbstract:
ABSTRACTObjectives:Behaviours associated with agitation are common in people living with dementia. The Cohen-Mansfield Agitation Inventory (CMAI) is a 29-item scale widely used to assess agitation completed by a proxy (family carer or staff member). However, proxy informants introduce possible reporting bias when blinding to the treatment arm is not possible, and potential accuracy issues due to irregular contact between the proxy and the person with dementia over the reporting period. An observational measure completed by a blinded researcher may address these issues, but no agitation measures with comparable items exist.Design:Development and validation of an observational version of the CMAI (CMAI-O), to assess its validity as an alternative or complementary measure of agitation.Setting:Fifty care homes in England.Participants:Residents (N = 726) with dementia.Measurements:Two observational measures (CMAI-O and PAS) were completed by an independent researcher. Measures of agitation, functional status, and neuropsychiatric symptoms were completed with staff proxies.Results:The CMAI-O showed adequate internal consistency (α = .61), criterion validity with the PAS (r = .79, p = < .001), incremental validity in predicting quality of life beyond the Functional Assessment Staging of Alzheimer's disease (β = 1.83, p < .001 at baseline) and discriminant validity from the Neuropsychiatric Inventory Apathy subscale (r = .004, p = .902).Conclusions:The CMAI-O is a promising research tool for independently measuring agitation in people with dementia in care homes. Its use alongside the CMAI could provide a more robust understanding of agitation amongst residents with dementia.
43
Hoang-Xuan, K., L. Capelle, M. Kujas, S. Taillibert, H. Duffau, J. Lejeune, M. Polivka, et al. "Temozolomide As Initial Treatment for Adults With Low-Grade Oligodendrogliomas or Oligoastrocytomas and Correlation With Chromosome 1p Deletions." Journal of Clinical Oncology 22, no. 15 (August 1, 2004): 3133–38. http://dx.doi.org/10.1200/jco.2004.10.169.
Full textAbstract:
Purpose To determine the response rate of low-grade oligodendroglial tumors (LGOT) to temozolomide (TMZ) as initial treatment and to evaluate the predictive value of chromosome 1p deletion on the radiologic response. Patients and Methods Adult patients with pathologically proven LGOT with progressive disease on magnetic resonance imaging (MRI) were eligible for the study. TMZ was administered at the starting dose of 200 mg/m2/d for 5 days, repeated every 28 days. Response was evaluated clinically and by central review of MRIs. Chromosome 1p and 19q deletions were detected by the loss of heterozygosity technique. Results Sixty consecutive patients were included in the study. At the time of analysis, the median number of TMZ cycles delivered was 11. Clinically, 51% of patients improved, particularly those with uncontrolled epilepsy. The objective radiologic response rate was 31% (17% partial response and 14% minor response), whereas 61% of patients had stable disease and 8% experienced disease progression. The median time to maximum tumor response was 12 months (range, 5 to 20 months). Myelosuppression was the most frequent side effect, with grade 3 to 4 toxicity in 8% of patients. Loss of chromosome 1p was associated with objective tumor response (P < .004). Conclusion TMZ is well tolerated and provides a substantial rate of response in LGOT. Chromosome 1p loss is correlated with radiographic response and could be a helpful marker for guiding therapeutic decision making in LGOT.
44
Crago, Elizabeth A., Paula R. Sherwood, Catherine Bender, Jeffrey Balzer, Dianxu Ren, and Samuel M. Poloyac. "Plasma Estrogen Levels Are Associated With Severity of Injury and Outcomes After Aneurysmal Subarachnoid Hemorrhage." Biological Research For Nursing 17, no. 5 (December 29, 2014): 558–66. http://dx.doi.org/10.1177/1099800414561632.
Full textAbstract:
Background:Biochemical mediators alter cerebral perfusion and have been implicated in delayed cerebral ischemia (DCI) and poor outcomes after aneurysmal subarachnoid hemorrhage (aSAH). Estrogens (estrone [E1] and estradiol [E2]) are mediators with neuroprotective properties that could play a role in DCI. This study explored associations between plasma estrogen levels and outcomes following aSAH.Methods:Plasma samples from 1–4, 4–6, and 7–10 days after hemorrhage from 99 adult aSAH patients were analyzed for estrogen levels using liquid chromatography tandem mass spectrometry. DCI was operationalized as radiographic/ultrasonic evidence of impaired cerebral blood flow accompanied by neurological deterioration. Outcomes were assessed using the Modified Rankin Scale at 3 and 12 months after hemorrhage. Statistical analysis included correlation, regression, and group-based trajectory.Results:Higher E1 and E2 levels were associated with higher Hunt and Hess grade (E1, p = .01; E2, p = .03), the presence of DCI (E1, p = .02; E2, p = .02), and poor 3-month outcomes (E1, p = .002; E2, p = .002). Trajectory analysis identified distinct populations over time for E1 (61% E1 high) and E2 (68% E2 high). Patients in higher trajectory groups had higher Fisher grades (E1, p = .008; E2, p = .01), more frequent DCI (E1, p = .04; E2, p = .08), and worse 3-month outcomes (E1, p = .01; E2, p = .004) than low groups.Conclusions:These results provide the first clinical evidence that plasma E1 and E2 concentrations are associated with severity of injury and outcomes after aSAH.
45
Balanzá, V., A. Tatay, S. Cepeda, T. Merino, M. Lloret, L. Laguna, and R. Calabuig. "Internet use by Patients with Psychiatric Disorders Searching for Medical Information." European Psychiatry 24, S1 (January 2009): 1. http://dx.doi.org/10.1016/s0924-9338(09)71124-1.
Full textAbstract:
Aims:Despite the increasing use of the Internet to seek medical information, little is known about the web search for mental health information among psychiatric patients. We aimed to identify the patients’ demographic and clinical characteristics that better predict the search for medical information, as well as the most consulted aspects of psychiatric disorders.Method:Over a one-month period, a consecutive series of patients followed at one Spanish hospital psychiatric outpatient clinic completed a 13-item questionnaire about their personal Internet use.Results:Among the 144 participating patients (72% women), 61% reported having ever used the Internet, with lower search rates for general health (34%) and mental health (22%) data. There were no differences by sex, but Internet use was more frequent among younger and higher-educated patients, as well as among those with eating disorders and personality disorders. Patients were most interested in diagnosis and treatment facets. A model with age (exp.β=1.05; p=.001) and high-school education (exp.β=5.55; p=.004) predicted searching for general medical information and correctly classified 75% of the sample (R2=0.3; p=0.004). Age was the only variable predicting specific search about mental health (exp.β=1.05; p=.001), and correctly classified 76% of patients (R2=0.2; p=0.001).Conclusions:The results of this one-site pilot study went in the anticipated direction and suggest that possible differences in the access to Internet according to the diagnostic group merit further research with multi-centre, larger samples.
46
Farinha, Pedro, Hamid Masoudi, Brian F. Skinnider, Karey Shumansky, John J. Spinelli, Karamjit Gill, Richard Klasa, Nicolas Voss, Joseph M. Connors, and Randy D. Gascoyne. "Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL)." Blood 106, no. 6 (September 15, 2005): 2169–74. http://dx.doi.org/10.1182/blood-2005-04-1565.
Full textAbstract:
Abstract We studied the role of multiple biomarkers in determining outcome in follicular lymphoma (FL), concentrating in particular on the role of benign macrophages. The study group consisted of uniformly staged and treated patients with FL enrolled in a phase 2 trial between 1987 and 1993. All patients were younger than 61 years of age, had advanced-stage FL, and were treated with a multiagent chemotherapy regimen, BP-VACOP (bleomycin, cisplatin, etoposide, doxorubicin, cyclophosphamide, vincristine, and prednisone), followed by involved region radiation. The median follow-up of living patients was 12.5 years, and the median survival was 16.3 years. The International Prognostic Index (IPI) was predictive of overall survival (OS) (P = .003). Biopsy specimens from all cases were stained with an anti-CD68 antibody. Of the 99 evaluable patients with FL, 87 had less than 15 CD68+ macrophages/high-power field (hpf) (median, 7; range, 1-14) and 12 had more than 15 CD68+ macrophages/hpf (median, 20; range, 16-25) with a median OS of 16.3 vs 5.0 years, respectively (P < .001). A multivariate Cox model that included the IPI score, the histologic grade, and the lymphoma-associated macrophage (LAM) score, showed IPI and LAM to be independent predictors of OS (P = .009 and P = .004, respectively). The LAM content of FL predicts survival, and these data support a prominent role for nonneoplastic immune cells in the biology of FL. (Blood. 2005;106:2169-2174)
47
Kasper, Andreas M., S. Andy Sparks, Matthew Hooks, Matthew Skeer, Benjamin Webb, Houman Nia, James P. Morton, and Graeme L. Close. "High Prevalence of Cannabidiol Use Within Male Professional Rugby Union and League Players: A Quest for Pain Relief and Enhanced Recovery." International Journal of Sport Nutrition and Exercise Metabolism 30, no. 5 (September 1, 2020): 315–22. http://dx.doi.org/10.1123/ijsnem.2020-0151.
Full textAbstract:
Rugby is characterized by frequent high-intensity collisions, resulting in muscle soreness. Players consequently seek strategies to reduce soreness and accelerate recovery, with an emerging method being cannabidiol (CBD), despite anti-doping risks. The prevalence and rationale for CBD use in rugby has not been explored; therefore, we recruited professional male players to complete a survey on CBD. Goodness of fit chi-square (χ2) was used to assess CBD use between codes and player position. Effects of age on use were determined using χ2 tests of independence. Twenty-five teams provided 517 player responses. While the majority of players had never used CBD (p < .001, V = 0.24), 26% had either used it (18%) or were still using it (8%). Significantly more CBD use was observed in rugby union compared with rugby league (p = .004, V = 0.13), but player position was not a factor (p = .760, V = 0.013). CBD use increased with players’ age (p < .001, V = 0.28), with mean use reaching 41% in the players aged 28 years and older category (p < .0001). The players using CBD primarily used the Internet (73%) or another teammate (61%) to obtain information, with only 16% consulting a nutritionist. The main reasons for CBD use were improving recovery/pain (80%) and sleep (78%), with 68% of players reporting a perceived benefit. These data highlight the need for immediate education on the risks of CBD, as well as the need to explore the claims regarding pain and sleep.
48
Hsieh, Chia-Yen, and Tim Chen. "Effect of Pokémon GO on the Cognitive Performance and Emotional Intelligence of Primary School Students." Journal of Educational Computing Research 57, no. 7 (June 25, 2019): 1849–74. http://dx.doi.org/10.1177/0735633119854006.
Full textAbstract:
The main purpose of this study is to analyze the effects of using Pokémon GO for 10 weeks on the cognitive performance (memory, selective attention, concentration, and creative imagination) and emotional intelligence (well-being, self-control, emotionality, and sociability) of Taiwanese primary students in the fifth and sixth grade. A mixed experimental design was used, with a control group (CG; n = 62) that did not use Pokémon GO, and an experimental group ( n = 61) that used Pokémon GO for 10 weeks. Confounders were age, sex, education level of the family, number of computers in the home, daily study time, and Internet access. The results showed that the players spent about 40 minutes/day on this game during this period. Boys played more and won more points in the game than girls. Compared against their peers, the players playing Pokémon GO showed a significant increase in their selective attention ( p = .025), concentration levels ( p = .004), creative imagination ( p < .001), emotionality ( p = .001), and sociability levels ( p = .005) but not memory, well-being, or self-control (all p > .05). It is concluded that Pokémon GO, in a playful way, could positively affect their cognitive performance (selective attention, concentration levels, and creative imagination) and improve their social relationships. However, if future researchers would like to ascertain whether Pokémon GO is a useful viable cognitive and social approach or not, more randomized controlled trial studies will be needed to compare Pokémon GO with traditional teaching approaches and educational methods.
49
Zelek, L., A. Llombart-Cussac, P. Terrier, X. Pivot, J. M. Guinebretiere, C. Le Pechoux, T. Tursz, F. Rochard, M. Spielmann, and A. Le Cesne. "Prognostic Factors in Primary Breast Sarcomas: A Series of Patients With Long-Term Follow-Up." Journal of Clinical Oncology 21, no. 13 (July 1, 2003): 2583–88. http://dx.doi.org/10.1200/jco.2003.06.080.
Full textAbstract:
Purpose: To describe the pathologic characteristics and prognostic factors of primary breast sarcomas (PBSs). Patients and Methods: We reviewed the clinical records and pathologic slides of 83 women with PBS treated in our institution between 1954 and 1991, with a median follow-up of 7.8 years. The majority of patients had undergone surgical treatment. Results: The main histologic type was malignant fibrohistiocytoma (n = 57). For the whole population, the 10-year overall survival (OS) and disease-free survival (DFS) rates were 62% and 50%, respectively. For Fédération Nationale des Centres de Lutte Contre le Cancer grade 1, 2, and 3 tumors, the 10-year OS and DFS rates were 82% and 61%, 62% and 51%, and 36% and 25%, respectively (P = .00007 and .004, respectively). For tumors measuring less than 5 cm, 5 to 10 cm, and more than 10 cm, the 10-year OS and DFS rates were 76% and 66%, 68% and 55%, and 28% and 15%, respectively (P = .002 and .009, respectively). In the multivariate analysis, the tumor size and histologic grade were correlated with the 10-year DFS rate (P = .04 and .01, respectively), but only the histologic grade was correlated with OS (P = .01). Angiosarcoma was the only histologic type significantly associated with a poorer outcome in the multivariate analysis. Conclusion: PBSs have the same clinical history and prognostic factors as sarcomas arising at other sites. Therefore, it is legitimate to use a similar treatment strategy for PBS as for other sarcomas.
50
Pott, Christiane, Eva Hoster, Marie-Helene Delfau-Larue, Kheira Beldjord, Sebastian Böttcher, Vahid Asnafi, Anne Plonquet, et al. "Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study." Blood 115, no. 16 (April 22, 2010): 3215–23. http://dx.doi.org/10.1182/blood-2009-06-230250.
Full textAbstract:
AbstractThe prognostic impact of minimal residual disease (MRD) was analyzed in 259 patients with mantle cell lymphoma (MCL) treated within 2 randomized trials of the European MCL Network (MCL Younger and MCL Elderly trial). After rituximab-based induction treatment, 106 of 190 evaluable patients (56%) achieved a molecular remission (MR) based on blood and/or bone marrow (BM) analysis. MR resulted in a significantly improved response duration (RD; 87% vs 61% patients in remission at 2 years, P = .004) and emerged to be an independent prognostic factor for RD (hazard ratio = 0.4, 95% confidence interval, 0.1-0.9, P = .028). MR was highly predictive for prolonged RD independent of clinical response (complete response [CR], complete response unconfirmed [CRu], partial response [PR]; RD at 2 years: 94% in BM MRD-negative CR/CRu and 100% in BM MRD-negative PR, compared with 71% in BM MRD-positive CR/CRu and 51% in BM MRD-positive PR, P = .002). Sustained MR during the postinduction period was predictive for outcome in MCL Younger after autologous stem cell transplantation (ASCT; RD at 2 years 100% vs 65%, P = .001) and during maintenance in MCL Elderly (RD at 2 years: 76% vs 36%, P = .015). ASCT increased the proportion of patients in MR from 55% before high-dose therapy to 72% thereafter. Sequential MRD monitoring is a powerful predictor for treatment outcome in MCL. These trials are registered at www.clinicaltrials.gov as #NCT00209222 and #NCT00209209.